PBS Generic Medicines Working Group communiques

27 January 2016 - The communiques from the first two meetings of the Generic Medicines Working Group are now available on ...

Read more →

NICE publishes final drug recommendations for 5 separate medical conditions

27 January 2016 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...

Read more →

NICE issues final guidance recommending 7 drugs for rheumatoid arthritis

26 January 2016 - In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs ...

Read more →

NICE draft guidance recommends nivolumab for advanced skin cancer

22 January 2016 - The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, ...

Read more →

CADTH calls for patient input on two submissions from Novartis for Cosentyx

21 January 2016 - CADTH has received notice of pending submissions from Novartis for Cosentyx (secukinumab) for use by patients with ...

Read more →

CADTH calls for patient input on a new submission from Celopharma for Mifegymiso

18 January 2016 - CADTH has received notice of a pending submission from Celopharma for Mifegymiso (mifepristone with misoprostol) for the ...

Read more →

Agenda for the 20 January 2016 TC meeting

18 January 2016 - The Transparency Commission will consider the reimbursement of dronedarone hydrochloride (Multaq), palonosetron hydrochloride (AloxI), lanreotide acetate ...

Read more →

Aclidinium bromide in COPD: evidence of significant additional value in certain patients

15 January 2016 - With reference to new scientific evidence, the manufacturer requested a reassessment and submitted a new dossier. ...

Read more →

CADTH calls for patient input on a new submission from AstraZeneca for Brilinta

15 January 2016 - CADTH has received notice of a pending submission from AstraZeneca for ticagrelor (Brilinta) for the prevention of ...

Read more →

Regorafenib in metastatic colorectal cancer: still only a hint of a minor additional benefit

4 January 2016 - After the expiry of the decision it made in 2014, the IQWIG has the reached same ...

Read more →

ERC recommends Jakavi for patients with polycythema vera who are resistant to or intolerant of hydroxyurea

7 January 2016 - The ERC has recommended the funding of ruxolitinib phosphate (Jakavi) so long as its cost-effectiveness is ...

Read more →

SMC announces more forthcoming submissions

13 January 2016 - The SMC has announced forthcoming submissions for the following medicines: brivaracetum (Briviact), cabazitaxel (Jevtana), crizotinib (Xalkori), febuxostat ...

Read more →

Nivolumab in melanoma: data subsequently submitted improve assessment result

7 January 2016 - In an addendum, the IQWiG assessed study data submitted by BMS. In treatment-naive patients whose tumour is ...

Read more →

Pomalidomide in multiple myeloma: no sign of an additional clinical benefit

4 January 2016 - The IQWiG examined whether pomalidomide offers an added benefit over the appropriate comparator therapy. No such added ...

Read more →

Dabrafenib in combination with trametinib in advanced melanoma with BRAF V600 mutation: indication of added benefit says IQWiG

4 January 2016 - According to the findings, no added benefit is proven for trametinib monotherapy because of a lack of ...

Read more →